What Can an Affordable Whole-Genome DNA Test Tell Me?

What can a whole-genome sequencing test tell me that an ancestry DNA test cannot?

Whole-genome sequencing can examine coding and noncoding regions across the genome, while many ancestry tests read a selected set of markers. That creates a broader sequence dataset, but not automatically a fuller health answer.

According to the National Human Genome Research Institute’s direct-to-consumer testing FAQ, many consumer health and ancestry products use SNP arrays. These check selected spots in DNA rather than reading the complete sequence. The FAQ describes ancestry arrays as using roughly 100,000 to 1 million markers.

Whole-genome sequencing uses next-generation sequencing to examine coding regions, which help provide instructions for proteins, and noncoding regions. Exome sequencing is narrower: it focuses on protein-coding regions. Even when a company sequences broadly, its report may display only a predetermined set of variants. The distinction is between what the lab reads and what the report chooses to explain.

Ancestry estimates also depend on comparison data. NHGRI notes that people from underrepresented populations can be misidentified when the reference data do not represent them well. More markers do not remove that dependence; the estimate still rests on the comparison set.

So the useful comparison is not “small test versus complete answer.” It is selected-marker testing versus broader sequencing, followed in both cases by a report with limits. Check whether the product offers sequencing or an array, which regions it covers, and which findings it reports.

Are at-home whole-genome sequencing results accurate?

An at-home test can accurately detect a DNA variant without accurately explaining what that variant means for your health. These are separate questions, and a consumer report should not be treated as a diagnosis.

The NHGRI guide to interpreting genomic reports explains that sequencing can identify potentially millions of differences from a reference sequence. Most have little or no known health impact, so interpretation requires filtering. A variant’s presence can be clearer than its significance; classifications can be uncertain and can change as evidence grows.

The guide says a reported variant is particularly likely to be truly present when a laboratory confirms it using a second method, such as Sanger sequencing. For a result that could affect medical care, ask whether the finding was confirmed and arrange clinical genetic testing through a healthcare professional. A consumer report is a starting point for that conversation, not the final clinical word.

Accuracy also varies by variant type and disease. Some variant types are not robustly detected, and test sensitivity differs across conditions. A negative result therefore has a narrow meaning: the test did not report a finding within its methods and scope. It does not prove that no genetic cause or risk exists.

Will a DNA test find every genetic risk variant?

No: a DNA test does not find every genetic risk variant, and a negative result cannot rule out a condition. The test’s coverage, detection limits, and report scope all shape what appears.

NHGRI states that direct-to-consumer tests often do not test for every disease-causing variant linked to a condition. A test may check a subset of variants, miss certain kinds of changes, or report only findings selected in advance. A “no variant detected” result is not the same as “no risk.”

Interpretation adds another limit. A detected difference may have uncertain significance, while a variant once judged concerning can be reclassified as evidence develops. Health risk also cannot be reduced to a list of DNA calls without considering what the test actually examined and what is known about each finding.

For a consumer checklist, ask what method was used, which variant types and conditions were covered, whether reported health findings receive confirmatory testing, and how uncertain findings are labeled. If a result suggests a serious or actionable risk, take it to a clinician and seek clinical confirmation before making medical decisions.

Privacy deserves the same close reading as the science. The Federal Trade Commission’s 2023 final order involving 1Health.io described failures involving promises about data sharing, destruction of DNA samples, and deletion of consumer data. The FTC complaint described publicly accessible health reports for nearly 2,400 consumers and raw genetic data for at least 227. The order required instructions to contract labs to destroy samples retained more than 180 days after analysis and barred health-data sharing with third parties without affirmative express consent.

That case makes the policy details concrete. Read the terms for biological samples separately from digital genetic data. Look for how research consent works, which third parties receive data, how to withdraw consent, how deletion requests work, and whether deletion covers stored samples as well as digital records. NHGRI also raises possible law-enforcement access as a privacy concern.

Legal protections have boundaries. NHGRI explains that the Genetic Information Nondiscrimination Act generally protects against genetic discrimination in health insurance and employment, subject to exceptions. It does not cover life, disability, or long-term care insurance; some states may add protections. A test result and its storage can therefore have implications beyond the immediate health report.